Where I see patients (2)
Class II HLA Variants Associate with Risk of Pegaspargase Hypersensitivity.
Clinical pharmacology and therapeutics
Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group.
Ponatinib With Chemotherapy in Pediatric Participants With Relapsed, Resistant, or Intolerant P...
The RP2D is the maximum tolerated dose (MTD) or less.
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Tender wagging care